enoxacin has been researched along with Bone Loss, Osteoclastic in 2 studies
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.
enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most agents for treating osteoporosis focus primarily on anti-resorption by inhibiting osteoclast activity." | 5.62 | Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment. ( Dai, M; Lai, Q; Li, X; Liu, X; Liu, Y; Mo, F; Xu, H; Xu, Q; Zhan, P; Zhang, B, 2021) |
| "Most agents for treating osteoporosis focus primarily on anti-resorption by inhibiting osteoclast activity." | 1.62 | Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment. ( Dai, M; Lai, Q; Li, X; Liu, X; Liu, Y; Mo, F; Xu, H; Xu, Q; Zhan, P; Zhang, B, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ostrov, DA | 1 |
| Magis, AT | 1 |
| Wronski, TJ | 1 |
| Chan, EK | 1 |
| Toro, EJ | 1 |
| Donatelli, RE | 1 |
| Sajek, K | 1 |
| Haroun, IN | 1 |
| Nagib, MI | 1 |
| Piedrahita, A | 1 |
| Harris, A | 1 |
| Holliday, LS | 1 |
| Xu, Q | 1 |
| Zhan, P | 1 |
| Li, X | 1 |
| Mo, F | 1 |
| Xu, H | 1 |
| Liu, Y | 1 |
| Lai, Q | 1 |
| Zhang, B | 1 |
| Dai, M | 1 |
| Liu, X | 1 |
2 other studies available for enoxacin and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
Topics: Actin Cytoskeleton; Actins; Animals; Binding Sites; Bone Marrow Cells; Bone Resorption; Cell Differe | 2009 |
Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment.
Topics: Actins; Animals; Biomarkers; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal | 2021 |